Bullish Trendline Has Never Failed Crispr Therapeutics Stock

Crispr Therapeutics AG (NASDAQ:CRSP) is 2.8% lower at $56.35 this afternoon, continuing a pullback from a Feb. 22, more than two-year high of$91.10. Over the last month, CRSP has erased 20.8% and now sports a 9.6% year-to-date deficit.For those looking to buy in on the dip, however, the recent pullback puts Crispr Therapeutics stock within one standard deviation of its 320-day moving average, a trendline with historically bullish implications. According to Schaeffer's Senior Quantitative Analyst Rocky Whit ...